Abstract
Two nitrogen mustard (N-mustard ) agents were synthesized utilizing ethylene diamine and hexane diamine as the parent compounds. These N-mustard agents were solids at 25°C and stable while stored dry at -10°C. The two N-mustards assumed the configuration of identical twin drugs which when placed in aqueous solution were highly reactive. Both N-mustards were soluble in aqueous NaHCO3 buffer and expressed alkylation activity directed towards a nucleophilic primary amine target (4-chloroaniline) at blood pH 7.4 and 37°C. Utilizing the fluorescent probe fluorescamine, which is highly specific for primary amines, the quantity of unreacted nucleophilic 4-chloroaniline remaining after a known time period was determined. This enabled the calculation of rate constants and the determination of rate equation for alkylation to be first-order for N,N,N,N-tetrakis(2-chloroethyl)ethane-1,2-diamine and zero-order for N,N,N,N- tetrakis(2-chloroethyl)hexane-1,6-diamine. Molecular property descriptors such as Log P, parachor, molar volume, molar refractivity, dipole, molecular volume & area, and polar surface area were calculated for comparison. Zero violations of the Rule of 5 indicates these two mustard agents will have good bioavailability and good bioactivity.
Keywords: nitrogen mustard, identical twin drug, alkylation
Letters in Drug Design & Discovery
Title: Two Identical Twin Nitrogen Mustard Agents that Express Rapid Alkylation Activity at Physiological pH 7.4 and 37°C
Volume: 1 Issue: 1
Author(s): Ronald Bartzatt and Laura Donigan
Affiliation:
Keywords: nitrogen mustard, identical twin drug, alkylation
Abstract: Two nitrogen mustard (N-mustard ) agents were synthesized utilizing ethylene diamine and hexane diamine as the parent compounds. These N-mustard agents were solids at 25°C and stable while stored dry at -10°C. The two N-mustards assumed the configuration of identical twin drugs which when placed in aqueous solution were highly reactive. Both N-mustards were soluble in aqueous NaHCO3 buffer and expressed alkylation activity directed towards a nucleophilic primary amine target (4-chloroaniline) at blood pH 7.4 and 37°C. Utilizing the fluorescent probe fluorescamine, which is highly specific for primary amines, the quantity of unreacted nucleophilic 4-chloroaniline remaining after a known time period was determined. This enabled the calculation of rate constants and the determination of rate equation for alkylation to be first-order for N,N,N,N-tetrakis(2-chloroethyl)ethane-1,2-diamine and zero-order for N,N,N,N- tetrakis(2-chloroethyl)hexane-1,6-diamine. Molecular property descriptors such as Log P, parachor, molar volume, molar refractivity, dipole, molecular volume & area, and polar surface area were calculated for comparison. Zero violations of the Rule of 5 indicates these two mustard agents will have good bioavailability and good bioactivity.
Export Options
About this article
Cite this article as:
Bartzatt Ronald and Donigan Laura, Two Identical Twin Nitrogen Mustard Agents that Express Rapid Alkylation Activity at Physiological pH 7.4 and 37°C, Letters in Drug Design & Discovery 2004; 1 (1) . https://dx.doi.org/10.2174/1570180043485789
DOI https://dx.doi.org/10.2174/1570180043485789 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Synthesis of Biologically Relevant Selenium-containing 5-Membered Heterocycles
Current Organic Chemistry NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry MicroRNAs as Critical Regulators Involved in Regulating Epithelial- Mesenchymal Transition
Current Cancer Drug Targets Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Proteomic Analysis of Phosphorylation in the Brain
Current Proteomics The Rationale for Repurposing Sildenafil for Lung Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry The Chemical Structure and Bioactivity of Cycloartane-type Compounds
Current Organic Chemistry Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Combination Treatment of p53-Null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression
Current Molecular Pharmacology Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy for the Peripheral Nervous System: A Strategy to Repair the Injured Nerve?
Current Gene Therapy Click Synthesis, Anticancer Activity and Molecular Docking Studies on Pyridazinone Scaffolds
Current Organic Chemistry